Skip to content

Pulse Oximetry- Performance During Severe Signal Interference

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01720355
Enrollment
17
Registered
2012-11-02
Start date
2012-08-31
Completion date
2012-11-30
Last updated
2013-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subjects

Brief summary

Determine accuracy specifications and labeling claims of a pulse oximeter in a diverse subject population during severe signal interference over a specified saturation range.

Interventions

None listed

Sponsors

Medtronic - MITG
Lead SponsorINDUSTRY

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

1. Male or female subjects between the ages of 18 to 50 years (inclusive). 2. Must undergo a physical examination by a licensed physician, advanced practice nurse or physician assistant, including a 12 lead ECG, a medical history, and a blood test checking complete blood count and screening for sickle cell trait or disease 3. All female volunteers must have a negative urine pregnancy test prior to participation.

Exclusion criteria

1. A room-air baseline % modulation \< 1.5% on all four fingers on the test hand 2. Pregnancy or lactating women 3. History of syncopal episodes 4. Hypertension (defined as a systolic pressure of \>145 mmHg or a diastolic pressure \>90 mm Hg on three consecutive readings) 5. Premature ventricular contractions (PVC's) that are symptomatic or occur at a rate of more than 5/minute 6. History of seizures (except childhood febrile seizures) or epilepsy 7. Routine use of tranquilizers and/or excessive anxiety 8. History of frequent headaches or migraines 9. History of stroke 10. Previous injury or trauma to fingers or hands that may change blood flow or vascular supply and affect our ability to test multiple sensors 11. History of altitude sickness defined as headaches, malaise or dizziness when in the mountains or in an aircraft at altitude significantly above sea level for a prolonged period of time (\> 1 hour) 12. History of significant respiratory disease, such as severe asthma, emphysema, etc. 13. Sickle cell disease or trait. 14. The use of medications, pre-existing medical conditions, treatment for a medical condition or any other reason deemed relevant by the clinician conducting the study. 15. A clinically significant abnormal finding on medical history, physical examination, clinical laboratory test or ECG. Clinical significance will be assessed by the principal investigator or designee. 16. Prior or known allergies to lidocaine (or similar pharmacologic agents, e.g., Novocain) 17. Prior or known allergies to heparin 18. History of transient ischemic attacks or carotid artery disease 19. History of myocardial ischemia, angina, myocardial infarction, congestive heart failure or cardiomyopathy 20. History of chronic renal impairment 21. History of recent arterial cannulation (less than 1 month prior to study) 22. History of complications from previous arterial cannulation 23. Current use of blood thinners

Design outcomes

Primary

MeasureTime frame
SpO2 Accuracy (percentage of blood oxygen saturation)1.5 hours per subject

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026